Viabilité
octobre 30, 2017
The federal health minister tabled a report from the Patented Medicine Prices Review Board (PMPRB) which shows that drugs with an annual per beneficiary cost of at least $10,000 accounted for 40% of patented drug sales in 2016. Furthermore, the cost of those high-priced medications doubled between 2006 and last year. The report finds that in 2016, patented drug sales increased by 2.6% to $15.5 billion, while drug sales rose an average of 4.1% between 2005 and last year.
Autres nouvelles:
La ministre fédérale de la Santé dépose le Rapport annuel 2016 du Conseil d'examen du prix des médicaments brevetés - Conseil d’examen du prix des médicaments brevetés
Sales of high-price drugs up 200% since 2006: PMPRB - Benefits Canada